Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 1042-1049

  Warnock, David G ^a   Ortiz, Alberto ^b   Mauer, Michael ^c   Linthorst, Gabor E ^d   Oliveira, João P ^e   Serra, Andreas L ^f   Maródi, László ^g   Mignani, Renzo ^h   Vujkovac, Bojan ⁱ   Beitner Johnson, Dana ^j   Lemay, Roberta ^j   Cole, Alexander ^j   Svarstad, Einar ^k   Waldek, Stephen ^l   Germain, Dominique P ^m   Wanner, Christoph ⁿ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF MINNESOTA   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g UNIVERSITY OF DEBRECEN   (Hungary)

^h Infermi Hospital   (Italy)

ⁱ General Hospital Slovenj Gradec   (Slovenia)

^j GENZYME CORPORATION   (United States)

^k HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^l SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^m LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

ⁿ UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

Alpha galactosidase; Enzyme replacement therapy; Fabry disease; Genetic renal disease; Proteinuria

Indexed keywords

AGALSIDASE BETA; CREATININE;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY INTERVENTION; FABRY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; URINARY EXCRETION;

ADULT; ALPHA-GALACTOSIDASE; CREATININE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ISOENZYMES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; TIME FACTORS;

EID: 84861168490     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr420     Document Type: Article

References (31)

1. Desnick RJ, Ioannou YA, Eng CM. Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W, Valle D, (eds). The Metabolic Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill, 2001: 3733-3774
2. Fogo AB, Bostad L, Svarstad E et al. Scoring systemfor renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25: 2168-2177
3. Gubler MC, Lenoir G, Grunfeld JP et al. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 1978; 13: 223-235
4. Thurberg BL, Rennke H, Colvin RB et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-1946
5. Valbuena C, Carvalho E, Bustorff M et al. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch 2008; 453: 329-338
6. Ortiz A, Cianciaruso B, Cizmarik M et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010; 25: 769-775
7. Schiffmann R, Warnock DG, Banikazemi M et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-2111
8. Sims K, Politei J, Banikazemi M et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009; 40: 788-794
9. Wilcox WR, Oliveira JP, Hopkin RJ et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008; 93: 112-128
10. Wanner C, Oliveira JP, Ortiz A et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 2010; 5: 2220-2228
11. Ortiz A, Oliveira JP, Waldek S et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23: 1600-1607
12. Mignani R, Feriozzi S, Schaefer RM et al. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol 2010; 5: 379-385
13. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16
14. Germain D, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547-1557
15. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146: 77-86
16. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
17. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285
18. Stevens LA, Coresh J, Greene T et al. Assessing kidney function- measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483
19. Breunig F,Weidemann F, Strotmann J et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006; 69: 1216-1221
20. Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5: 30
21. West M, Nicholls K, Mehta A et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20: 1132-1139
22. Ortiz A, Oliveira JP, Wanner C et al. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol 2008; 4: 327-336
23. Warnock DG, Daina E, Remuzzi G et al. Enzyme replacement therapy and Fabry nephropathy. Clin J Am Soc Nephrol 2010; 5: 371-378
24. Mehta A, West ML, Pintos-Morell G et al. Therapeutic goals in the treatment of Fabry disease. Genet Med 2010; 12: 713-720
25. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18: 2609-2617
26. Mehta A, Beck M, Elliott P et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009; 374: 1986-1996
27. Waldek S, Germain DP, Wanner C et al. Enzyme replacement therapy for Fabry's disease. Lancet 2010; 375: 1523-1524
28. Schiffmann R, Askari H, Timmons M et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007; 18: 1576-1583
29. Nakao S, Kodama C, Takenaka T et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a ''renal variant'' phenotype. Kidney Int 2003; 64: 801-807
30. Spada M, Pagliardini S, Yasuda M et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31-40
31. Tondel C, Bostad L, Hirth A et al. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 2008; 51: 767-776